MONMOUTH JUNCTION, N.J.,
March 13, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company using blood purification to treat
life-threatening illnesses in the intensive care unit, announced
that it will sponsor a research symposium entitled:
"SIRS and SEPSIS – New Therapy with
CytoSorb®"
at the 34th International Symposium on Intensive Care
and Emergency Medicine (ISICEM 2014) in Brussels, Belgium next week. The program
is scheduled for Wednesday, March 19,
2014 from 6:15 – 7:45 PM in
the ARC room of the Square – Brussels Meeting Center.
Refreshments will be served.
Distinguished physicians will discuss the application of
CytoSorb® extracorporeal cytokine reduction in sepsis and other
inflammatory conditions, such as cardiac surgery.
- Dr. Herwig Gerlach (Berlin, Germany): "Overshooting the
inflammatory response – The Root of all Evil?"
- Dr. John Kellum (Pittsburgh, USA): Blood purification in SIRS and Sepsis: A
new paradigm"
- Dr. Michael Quintel (Gottingen,
Germany): Clinical Experience:
Severe sepsis/ septic shock and CytoSorb® therapy
- Dr. Karl Trager (Ulm,
Germany): Clinical
Experience: Post-Cardiopulmonary Bypass SIRS and CytoSorb®
therapy.
In addition, attendees can visit CytoSorbents' exhibit booth in
the Silver Foyer, Booth S.01 from March
18-21, 2014 to learn more about CytoSorb® immunotherapy for
critical illnesses and how, through cytokine reduction, it targets
a reduction of the potentially deadly systemic inflammatory
response syndrome (SIRS) in order to prevent or treat organ failure
and improve clinical outcomes.
About ISICEM
The International Symposium on Intensive Care and Emergency
Medicine is organized by the Departments of Intensive Care and
Emergency Medicine of Erasme University Hospital, Universite Libre
de Bruxelles, in association with
the Belgian Society of Intensive Care and Emergency Medicine. This
annual conference was started in 1980 and has become established as
one of the largest in its field, now attracting more than 6,000
participants from countries worldwide. The objectives of this
four-day symposium are to provide participants with an up-to-date
review of the most recent, clinically relevant, developments in
research, therapy, and management of the critically ill. The
meeting is open to all physicians, nurses, and other health
professionals with an interest in critical care or emergency
medicine.
About CytoSorbents
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to modulate
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. CytoSorbents has numerous
products under development based upon this unique blood
purification technology, protected by 32 issued US patents and
multiple applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: http://www.cytosorbents.com/
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release are not promises or guarantees and
are subject to risks and uncertainties that could cause our actual
results to differ materially from those anticipated. These
statements are based on management's current expectations and
assumptions and are naturally subject to uncertainty and changes in
circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ
materially from those expressed or implied by the statements
herein. Risk factors are detailed in the Company's Form 10-K filed
with the SEC on April 3, 2013, which
is available at http://www.sec.gov.
Please Click to Follow us on Facebook and
Twitter
SOURCE CytoSorbents Corporation